Long noncoding RNA ZEB1‐AS1 attenuates ferroptosis of gastric cancer cells through modulating miR‐429/BGN axis

Abstract

AbstractGastric cancer (GC) is the fifth utmost common malignant cancer type globally, in which ferroptosis acts a critical function in the progress of GC. Long noncoding RNA ZEB1‐AS1 has been recognized in numerous cancers, but the role of ZEB1‐AS1 in ferroptosis remains obscure. Hence, we investigated the efficacy of ZEB1‐AS1 on ferroptosis of GC cells. The cell growth and viability were analyzed via cell counting kit assay and xenograft tumor model in vivo and in vitro, respectively. The RNA and protein expression were measured by qRT‐PCR and western blot analysis assay, respectively. The levels of Fe2+, malondialdehyde (MDA), and lipid reactive oxygen species (ROS) were tested to determine ferroptosis. The erastin and RSL3 were used to induce ferroptosis. The mechanism was analyzed via luciferase reporter gene and RIP assays. The treatment of ferroptosis inducer Erastin and RSL3 suppressed the viability of GC cells and the ZEB1‐AS1 overexpression rescued the phenotype in the cells. The levels of Fe2+, MDA, and ROS were enhanced through the depletion of ZEB1‐AS1 in Erastin/RSL3 treated GC cells. ZEB1‐AS1 directly sponged miR‐429 in GC cells and miR‐429 targeted BGN in GC cells, and the inhibition of miR‐429 rescued ZEB1‐AS1 depletion‐inhibited BGN expression. We validated that miR‐429 induced and BGN‐repressed ferroptosis in cancer cells. The BGN overexpression and miR‐429 suppression could reverse the efficacy of ZEB1‐AS1 on proliferation and ferroptosis in cancer cells. The expression of ZEB1‐AS1 and BGN was enhanced and miR‐429 expression was decreased in clinical GC tissues. ZEB1‐AS1 attenuated ferroptosis of cancer cells by modulating miR‐429/BGN axis.